First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT02236975

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02236975
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Netherlands, Portugal, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02236975. Randomized; single masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2016-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Intervention (Device)
BuMA Supreme Biodegradable drug coating coronary stent system
Intervention (Device)
Resolute Integrity durable polymer stent system
Lead sponsor
Sino Medical Sciences Technology Inc. (class: industry)

Record details

Record id
cardio:ct-nct02236975
Content hash
7f037c9c04d2c66477c7a3a0877aedfc3ee47ac2bf082c8a7ed8946710f85bc4